Genitourinary Cancers

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, comments on the FDA approval of the combination of lenvatinib (Lenvima) and everolimus (Afinitor) as a treatment for patients with advanced renal cell carcinoma (RCC) following prior anti–angiogeneic therapy.

The FDA has approved the combination of lenvatinib and everolimus as a treatment for patients with advanced renal cell carcinoma (RCC) following prior anti–angiogeneic therapy

Mohammed Haseebuddin, MD, discusses results of a study which demonstrated that elevated preoperative classical monocyte PD-1 mean fluorescence intensity level and lower CM was linked to poor survival in patients with clear cell renal cell carcinoma, as well as the challenges with using PD-1 as a biomarker in these patients.

Robert Dreicer, MD, provides insight on the IMvigor 210 study and how atezolizumab will dramatically change the treatment paradigm for patients with metastatic urothelial carcinoma, who have a severe unmet need.

Krishna Vanaja Donkena, PhD, Assistant Professor of Biochemistry and Molecular Biology, Center for Individualized Medicine, Mayo Clinic, discusses using immune and checkpoint markers to predict cancer-specific survival in bladder cancer.

TMX-101 (Vesimune), a liquid formulation of the toll-like receptor 7 agonist imiquimod, appeared safe and demonstrated preliminary clinical activity, including the potential to induce an immune response, in patients with non-muscle invasive bladder cancer.

Mark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti–PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.

Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.

Xifeng Wu, MD, PhD, chair, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, director, Center for Translational and Public Health Genomics, professor, The University of Texas MD Anderson Cancer Center, discusses the prognostic factor of obesity-related genes in patients with renal cell carcinoma (RCC).

Robert Pili, MD, discusses the results and significance of an early-phase trial looking at the combination of entinostat and interleuken-2 and how it could shake up the treatment paradigm for renal cell carcinoma.

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, comments on the FDA approval of cabozantinib as a second-line treatment of patients with renal cell carcinoma (RCC).

The FDA has approved cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy.

Robert Figlin, MD, discusses some emerging agents and ongoing trials that could transform the treatment landscape of renal cell carcinoma.

Sumanta Kumar Pal, MD, discusses the state of biomarker development in the field of genitourinary malignancies.

More than one-third of patients with previously untreated renal cell carcinoma responded to the combination of high-dose interleukin-2 and an investigational histone deacetylase inhibitor entinostat.

Although therapeutic options for renal cell carcinoma have expanded dramatically during the past decade, oncologists are faced with considerable complexity in selecting the right course of treatment for the individual patient.

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses why community oncologists should utilize immunotherapy agents to treat patients with renal cell carcinoma.

At Metro Urology of Minneapolis, urologists are at the forefront of introducing new techniques and technology, especially with respect to advanced prostate cancer care.

The European Commission has approved nivolumab (Opdivo) for use in previously treated patients with advanced renal cell carcinoma.

Immunotherapy should be considered along with VEGF and mTOR TKIs as a highly effective treatment modality for patients with metastatic renal cell carcinoma.

Alexander Kutikov, MD, discusses the evolving role of surgery in kidney cancer.

Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses immunotherapy agents for the treatment of patients with bladder cancer.

Mario Sznol, MD, discusses the current state of immunotherapy in renal cell carcinoma, emerging agents and combinations in the field, and the challenges that arise with finding biomarkers.

Katherine Krajewski, MD, associate director, physician, Cancer Imaging Program Fellowship, Dana-Farber Cancer Institute, assistant professor of Radiology, Harvard Medical School, discusses the range of responses seen in patients with renal cell carcinoma (RCC) who have received PD-1 agents as treatment.